Understanding CVS Health/McKesson and Why Pharmacies Lose Money on GLP-1s (rerun)
Drug Channels
APRIL 1, 2024
Consider two apparently unrelated drug channel anomalies: In McKesson’s 2023 fiscal year, CVS bought $75 billion in pharmaceuticals from McKesson’s wholesale business—a jump of more than 35% compared with the previous year. Despite skyrocketing sales for anti-obesity GLP-1 drugs, many retail pharmacies are losing money on every prescription.
Let's personalize your content